Galectin Therapeutics Files 8-K with Material Agreement, Director Changes
Ticker: GALT · Form: 8-K · Filed: Jul 9, 2025 · CIK: 1133416
| Field | Detail |
|---|---|
| Company | Galectin Therapeutics INC (GALT) |
| Form Type | 8-K |
| Filed Date | Jul 9, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, corporate-governance, filing
Related Tickers: GALT
TL;DR
GALECTIN THERAPEUTICS (GALT) filed an 8-K: material agreement signed, board/officer changes. Details TBD.
AI Summary
Galectin Therapeutics Inc. announced on July 8, 2025, the entry into a material definitive agreement and changes in its board of directors and officer compensation. The company also filed financial statements and exhibits as part of this report. Specific details regarding the agreement and compensation arrangements were not provided in this excerpt.
Why It Matters
This filing indicates significant corporate actions, including a new material agreement and potential changes in leadership or compensation, which could impact the company's strategic direction and investor outlook.
Risk Assessment
Risk Level: medium — The filing involves material definitive agreements and changes in corporate governance, which can introduce uncertainty or signal significant strategic shifts.
Key Players & Entities
- Galectin Therapeutics Inc. (company) — Registrant
- Nevada (jurisdiction) — State of Incorporation
- Norcross, GA (location) — Principal Executive Office
- July 8, 2025 (date) — Date of earliest event reported
FAQ
What is the nature of the material definitive agreement entered into by Galectin Therapeutics Inc.?
The filing indicates the entry into a material definitive agreement, but the specific details of this agreement are not provided in the excerpt.
What specific changes occurred regarding directors or officers?
The filing reports the departure of directors or certain officers, election of directors, and appointment of certain officers, along with details on compensatory arrangements, but the excerpt does not name individuals or specify the changes.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing was on July 8, 2025.
What is the principal executive office address for Galectin Therapeutics Inc.?
The principal executive office of Galectin Therapeutics Inc. is located at 4960 Peachtree Industrial Boulevard, Suite 240, Norcross, GA 30071.
What is the Commission File Number for Galectin Therapeutics Inc.?
The Commission File Number for Galectin Therapeutics Inc. is 001-31791.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on July 9, 2025 regarding GALECTIN THERAPEUTICS INC (GALT).